Literature DB >> 25378633

Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma.

Christine Marosi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25378633      PMCID： PMC4483056          DOI： 10.1093/neuonc/nou315

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  8 in total

Review 1.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

Review 2.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.

Authors:  Thomas Kaley; Igor Barani; Marc Chamberlain; Michael McDermott; Katherine Panageas; Jeffrey Raizer; Leland Rogers; David Schiff; Michael Vogelbaum; Damien Weber; Patrick Wen
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

3.  Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.

Authors:  Peter Horak; Adelheid Wöhrer; Marco Hassler; Johannes Hainfellner; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

4.  A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

Authors:  Markus Hutterer; Martha Nowosielski; Johannes Haybaeck; Sabine Embacher; Florian Stockhammer; Thaddäus Gotwald; Bernhard Holzner; David Capper; Matthias Preusser; Christine Marosi; Stefan Oberndorfer; Martin Moik; Johanna Buchroithner; Marcel Seiz; Jochen Tuettenberg; Ulrich Herrlinger; Antje Wick; Peter Vajkoczy; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

5.  Atypical and anaplastic meningiomas treated with bevacizumab.

Authors:  Lakshmi Nayak; Fabio M Iwamoto; Jeremy D Rudnick; Andrew D Norden; Eudocia Quant Lee; Jan Drappatz; Antonio Omuro; Thomas J Kaley
Journal:  J Neurooncol       Date:  2012-04-29       Impact factor: 4.130

6.  Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches.

Authors:  Matthias Preusser; Marco Hassler; Peter Birner; Margaretha Rudas; Till Acker; Karl H Plate; Georg Widhalm; Engelbert Knosp; Helene Breitschopf; Johannes Berger; Christine Marosi
Journal:  Clin Neuropathol       Date:  2012 Sep-Oct       Impact factor: 1.368

7.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

8.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Authors:  Thomas J Kaley; Patrick Wen; David Schiff; Keith Ligon; Sam Haidar; Sasan Karimi; Andrew B Lassman; Craig P Nolan; Lisa M DeAngelis; Igor Gavrilovic; Andrew Norden; Jan Drappatz; Eudocia Quant Lee; Benjamin Purow; Scott R Plotkin; Tracy Batchelor; Lauren E Abrey; Antonio Omuro
Journal:  Neuro Oncol       Date:  2014-08-06       Impact factor: 12.300
  8 in total
  1 in total

1.  Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo.

Authors:  Hiroyuki Takeda; Masashi Okada; Kenta Kuramoto; Shuhei Suzuki; Hirotsugu Sakaki; Tomomi Sanomachi; Shizuka Seino; Takashi Yoshioka; Hirofumi Hirano; Kazunori Arita; Chifumi Kitanaka
Journal:  Oncotarget       Date:  2017-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.